Review



components  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    MedChemExpress components
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Components, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 132 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/components/product/MedChemExpress
    Average 96 stars, based on 132 article reviews
    components - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression"

    Article Title: Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

    Journal: bioRxiv

    doi: 10.64898/2026.04.26.720919

    A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Figure Legend Snippet: A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

    Techniques Used: In Vivo, Ex Vivo, Control, Imaging



    Similar Products

    pathway components  (Shanghai Korain Biotech Co Ltd)
    93
    Shanghai Korain Biotech Co Ltd pathway components
    Pathway Components, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway components/product/Shanghai Korain Biotech Co Ltd
    Average 93 stars, based on 1 article reviews
    pathway components - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    components  (MedChemExpress)
    96
    MedChemExpress components
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Components, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/components/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    components - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    components  (Fuzheng Pharmaceutical Co Ltd)
    86
    Fuzheng Pharmaceutical Co Ltd components
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Components, supplied by Fuzheng Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/components/product/Fuzheng Pharmaceutical Co Ltd
    Average 86 stars, based on 1 article reviews
    components - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    onlay components  (Stryker)
    86
    Stryker onlay components
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Onlay Components, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/onlay components/product/Stryker
    Average 86 stars, based on 1 article reviews
    onlay components - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    inlay components  (Stryker)
    86
    Stryker inlay components
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Inlay Components, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inlay components/product/Stryker
    Average 86 stars, based on 1 article reviews
    inlay components - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    c9 1 200 novus biologicals nbp2 15952  (Novus Biologicals)
    86
    Novus Biologicals c9 1 200 novus biologicals nbp2 15952
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    C9 1 200 Novus Biologicals Nbp2 15952, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c9 1 200 novus biologicals nbp2 15952/product/Novus Biologicals
    Average 86 stars, based on 1 article reviews
    c9 1 200 novus biologicals nbp2 15952 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp  (Frontier Specialty Chemicals Inc)
    95
    Frontier Specialty Chemicals Inc component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Component Platinum Ii Meso Tetrakis Pen Tafluorophenyl Porphyrin Pttfpp, supplied by Frontier Specialty Chemicals Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp/product/Frontier Specialty Chemicals Inc
    Average 95 stars, based on 1 article reviews
    component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    xtension component  (Oxford Instruments)
    99
    Oxford Instruments xtension component
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Xtension Component, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/xtension component/product/Oxford Instruments
    Average 99 stars, based on 1 article reviews
    xtension component - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    components components anionic surfactant  (Dow Chemical)
    86
    Dow Chemical components components anionic surfactant
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Components Components Anionic Surfactant, supplied by Dow Chemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/components components anionic surfactant/product/Dow Chemical
    Average 86 stars, based on 1 article reviews
    components components anionic surfactant - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    molecular weight components g mol amount  (Croda International Plc)
    99
    Croda International Plc molecular weight components g mol amount
    A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
    Molecular Weight Components G Mol Amount, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/molecular weight components g mol amount/product/Croda International Plc
    Average 99 stars, based on 1 article reviews
    molecular weight components g mol amount - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

    Journal: bioRxiv

    Article Title: Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

    doi: 10.64898/2026.04.26.720919

    Figure Lengend Snippet: A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

    Article Snippet: The following components were purchased from MedChemExpress; DLin-MC3-DMA (HY-112251), DOTAP (HY-112754A), 306-O12B (HY-W590532), DMG-PEG 2000 (HY-112764), DOPC (HY-113424A), and DSPE-PEG-Maleimide (HY-140740).

    Techniques: In Vivo, Ex Vivo, Control, Imaging